Centrus Energy (LEU) has signaled its next move in rebuilding America's nuclear fuel supply chain: a potential acquisition of a U.S. manufacturing supplier for roughly $115 million to $125 million. The disclosure, buried in a late Friday Form 8-K, reveals the target generated about $160 million in 2025 revenue, implying a headline valuation of just 0.72 to 0.78 times sales.
At the $120 million midpoint, that translates to 0.75 times the target's 2025 revenue. The supplier is not small relative to Centrus: its $160 million in sales nearly matches Centrus's second-quarter revenue of $176.1 million and represents about 63% of the company's first-half revenue of $252.8 million, based on the June-quarter report.
However, the price-to-sales multiple alone offers little insight into whether the deal is a bargain. Investors lack critical details such as the target's margins, cash flow, debt load, customer concentration, and capital requirements. Without these, a low multiple could mask a troubled operation or a hidden gem.
To illustrate, a $120 million purchase price implies an EBITDA of $8 million at a 5% margin (15x EBITDA), $16 million at 10% (7.5x), or $24 million at 15% (5x). A low-margin fabricator at 15 times hypothetical EBITDA would tell a very different story from a specialized supplier with scarce certifications and capacity that Centrus would otherwise have to build itself.
Centrus can likely fund the deal. The company reported $1.87 billion in cash and cash equivalents at June 30, against $1.18 billion in long-term debt. But that cash is not idle: Centrus spent $94.8 million on capital projects in the first half, up from $5.7 million a year earlier, and used $16.7 million in operating cash as it invests in domestic enrichment capacity.
The timing coincides with Centrus's $500 million securities offering announced on September 9. Proceeds from that offering may be used for acquisitions, technology, capital spending, debt, and working capital. A $120 million purchase would equal 24% of the offering's expected gross proceeds before fees.
The offering includes 500,000 common shares, pre-funded warrants for 2,005,513 shares, and common warrants for up to 6,992,382 shares. The lowest common-warrant exercise price of $226.8625 sits about 49% above Friday's close, so those warrants are not an immediate funding source at current prices. Still, the common shares and pre-funded warrants expand the share count now.
LEU shares closed Friday at $152.31, down 8.18%, on volume of ~1.1 million shares. The market was also absorbing the securities offering, so the decline cannot be attributed solely to the acquisition news.
The industrial logic is plausible: Centrus is scaling U.S. centrifuge manufacturing and uranium enrichment, and owning a supplier could secure capacity, shorten lead times, or protect specialized know-how. Such benefits could justify a premium over what a financial buyer would pay for the target's stand-alone earnings.
Yet vertical integration carries risks—turning flexible supplier relationships into fixed costs, working-capital needs, and execution risk. Without the target's identity, investors cannot assess customer concentration, related-party exposure, government-contract dependence, or whether $160 million was a normal sales year.
A definitive announcement would need to disclose the consideration mix, assumed liabilities, historical profit and cash flow, major-customer concentration, expected synergies, and a closing timetable. Until then, the 0.75-times-sales figure is a useful clue—but not proof that Centrus has found a bargain.
